Association between the XRCC1 Arg194Trp Polymorphism and Glioma Risk: an Updated Meta-analysis

  • Xu, Cheng (State Key Laboratory of Reproductive Medicine, Institute of Toxicology, Nanjing Medical University) ;
  • Chen, Pin (Department of Neurosurgery, The First Affiliated Hospital, Nanjing Medical University) ;
  • Liu, Wei (State Key Laboratory of Reproductive Medicine, Institute of Toxicology, Nanjing Medical University) ;
  • Gu, Ai-Hua (State Key Laboratory of Reproductive Medicine, Institute of Toxicology, Nanjing Medical University) ;
  • Wang, Xin-Ru (State Key Laboratory of Reproductive Medicine, Institute of Toxicology, Nanjing Medical University)
  • Published : 2014.09.15


Gliomas are the most common type of primary brain tumors. The XRCC1 Arg194Trp variant affects the proliferating cell nuclear antigen(PCNA) binding region, which suggests that this mutation may contribute to gliomagenesis and a number of articles have examine the association between XRCC1 Arg194Trp and the susceptibility to glioma. However, the results were conflicting. Test of heterogeneity, sensitivity analysis, meta-analysis, and assessment of publication bias were all performed in our present meta-analysis, covering a total of 5,407 patients and 7,715 healthy persons. In the overall analysis the XRCC1 Arg194Trp polymorphism showed a significant association with glioma susceptibility in a recessive mode l(for TrpTrp vs ArgArg+ArgTrp: OR=1.918, 95%CI=1.575-2.336, $I^2$=2.3%). In addition, analysis of subgroups presented an increased risk in Asians and populations-based on hospitals. The results suggested that the XRCC1 Arg194Trp polymorphism is a genetic risk factor for glioma, especially in Asian population. To further evaluate gene-gene and gene-environment interactions on XRCC1 polymorphisms and glioma risk, thousands of subjects and tissue-specific biochemical characterizations are required.


  1. Akbari M, Solvang-Garten K, Hanssen-Bauer A, et al (2010). Direct interaction between XRCC1 and UNG2 facilitates rapid repair of uracil in DNA by XRCC1 complexes. DNA Repair, 9, 785-95.
  2. Bondy ML, Scheurer ME, Malmer B, et al (2008). Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer, 113, 1953-68.
  3. Caldecott KW, Tucker JD, Stanker LH, Thompson LH (1995). Characterization of the XRCC1-DNA ligase III complex in vitro and its absence from mutant hamster cells. Nucleic Acids Res, 23, 4836-43.
  4. Campalans A, Marsin S, Nakabeppu Y, et al (2005). XRCC1 interactions with multiple DNA glycosylases: a model for its recruitment to base excision repair. DNA Repair, 4, 826-35.
  5. Connelly JM, Malkin MG (2007). Environmental risk factors for brain tumors. Curr Neurol Neurosci Rep, 7, 208-14.
  6. Custodio AC, Almeida LO, Pinto GR, et al (2011). Analysis of the polymorphisms XRCC1Arg194Trp and XRCC1Arg399Gln in gliomas. Genet Mol Res, 10, 1120-9.
  7. Dianov GL, Prasad R, Wilson SH, Bohr VA (1999). Role of DNA polymerase beta in the excision step of long patch mammalian base excision repair. J Biol Chem, 274, 13741-3.
  8. Freely associating (1999). Nat Genet, 22, 1-2.
  9. Hu XB, Feng Z, Fan YC, Xiong ZY, Huang QW (2011). Polymorphisms in DNA repair gene XRCC1 and increased genetic susceptibility to glioma. Asian Pac J Cancer Prev, 12, 2981-4.
  10. Hu Z, Ma H, Chen F, Wei Q, Shen H (2005). XRCC1 polymorphisms and cancer risk: a meta-analysis of 38 case-control studies. Cancer Epidemiol Biomarkers Prev, 14, 1810-8.
  11. Jiang L, Fang X, Bao Y, et al (2013). Association between the XRCC1 polymorphisms and glioma risk: a meta-analysis of case-control studies. PLoS One, 8, 55597.
  12. Kishida Y, Natsume A, Toda H, et al (2012). Correlation between quantified promoter methylation and enzymatic activity of O6-methylguanine-DNA methyltransferase in glioblastomas. Tumour Biol, 33, 373-81.
  13. Kiuru A, Lindholm C, Heinavaara S, et al (2008). XRCC1 and XRCC3 variants and risk of glioma and meningioma. J Neurooncol, 88, 135-42.
  14. Liu HB, Peng YP, Dou CW, et al (2012). Comprehensive study on associations between nine SNPs and glioma risk. Asian Pac J Cancer Prev, 13, 4905-8.
  15. Liu Y, Scheurer ME, El-Zein R, et al (2009). Association and interactions between DNA repair gene polymorphisms and adult glioma. Cancer Epidemiol Biomarkers Prev, 18, 204-14.
  16. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN (2003). Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet, 33, 177-82.
  17. Luo KQ, Mu SQ, Wu ZX, Shi YN, Peng JC (2013). Polymorphisms in DNA repair genes and risk of glioma and meningioma. Asian Pac J Cancer Prev, 14, 449-52.
  18. Marsin S, Vidal AE, Sossou M, et al (2003). Role of XRCC1 in the coordination and stimulation of oxidative DNA damage repair initiated by the DNA glycosylase hOGG1. J Biol Chem, 278, 44068-74.
  19. Marumoto T, Saya H (2012). Molecular biology of glioma. Adv Exp Med Biol, 746, 2-11.
  20. McKean-Cowdin R, Barnholtz-Sloan J, Inskip PD, et al (2009). Associations between polymorphisms in DNA repair genes and glioblastoma. Cancer Epidemiol Biomarkers Prev, 18, 1118-26.
  21. Melin B (2011). Genetic causes of glioma: new leads in the labyrinth. Curr Opin Oncol, 23, 643-7.
  22. Monaco R, Rosal R, Dolan MA, Pincus MR, Brandt-Rauf PW (2007). Conformational effects of a common codon 399 polymorphism on the BRCT1 domain of the XRCC1 protein. Protein J, 26, 541-6.
  23. Ostrom QT, Barnholtz-Sloan JS (2011). Current state of our knowledge on brain tumor epidemiology. Curr Neurol Neurosci Rep, 11, 329-35.
  24. Pan WR, Li G, Guan JH (2013). Polymorphisms in DNA repair genes and susceptibility to glioma in a chinese population. Int J Mol Sci, 14, 3314-24.
  25. Rajaraman P, Hutchinson A, Wichner S, et al (2010). DNA repair gene polymorphisms and risk of adult meningioma, glioma, and acoustic neuroma. Neuro Oncol, 12, 37-48.
  26. Ricard D, Idbaih A, Ducray F, et al (2012). Primary brain tumours in adults. Lancet, 379, 1984-96.
  27. Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M (2006). Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol, 2, 494-503.
  28. Thompson LH, West MG (2000). XRCC1 keeps DNA from getting stranded. Mutat Res, 459,1-18.
  29. Vidal AE, Boiteux S, Hickson ID, Radicella JP (2001). XRCC1 coordinates the initial and late stages of DNA abasic site repair through protein-protein interactions. EMBO J, 20, 6530-9.
  30. von Deimling A, Korshunov A, Hartmann C (2011). The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol, 21, 74-87.
  31. Wacholder S, Rothman N, Caporaso N (2002). Counterpoint: bias from population stratification is not a major threat to the validity of conclusions from epidemiological studies of common polymorphisms and cancer. Cancer Epidemiol Biomarkers Prev, 11, 513-20.
  32. Wang D, Hu Y, Gong H, et al (2012). Genetic polymorphisms in the DNA repair gene XRCC1 and susceptibility to glioma in a Han population in northeastern China: a case-control study. Gene, 509, 223-7.
  33. Wen PY, Kesari S (2008). Malignant gliomas in adults. N Engl J Med, 359, 492-507.
  34. Xu G, Wang M, Xie W, Bai X (2013). Three polymorphisms of DNA repair gene XRCC1 and the risk of glioma: a casecontrol study in northwest China. Tumour Biol.???
  35. Zhou LQ, Ma Z, Shi XF, et al (2011). Polymorphisms of DNA repair gene XRCC1 and risk of glioma: a case-control study in Southern China. Asian Pac J Cancer Prev, 12, 2547-50.

Cited by

  1. Variant Alleles in XRCC1 Arg194Trp and Arg399Gln Polymorphisms Increase Risk of Gastrointestinal Cancer in Sabah, North Borneo vol.17, pp.4, 2016,
  2. Polymorphisms in DNA Repair Gene and Susceptibility to Glioma: A Systematic Review and Meta-Analysis Based on 33 Studies with 15 SNPs in 9 Genes vol.37, pp.2, 2017,
  3. XRCC1 polymorphism and overall survival in ovarian cancer patients treated with platinum-based chemotherapy vol.97, pp.45, 2018,